Drug intelligence / Profile preview

ps297

Development stage: Preclinical
Modality: Small Molecules

Overview

ps297 is a preclinical GPR119 agonist compound developed for its potential to target gut enteroendocrine cells (EECs) and stimulate glucagon-like peptide-1 (GLP-1) secretion. It is characterized by low gut permeability and poor systemic bioavailability, making it a gut-restricted agent. The primary mechanism of action involves activation of the GPR119 receptor, which is expressed in EECs and plays a role in glucose homeostasis[4][1]. Preclinical studies have demonstrated acute safety, efficacy, and favorable pharmacokinetic profiles for ps297[1].

Targets

GPR119 (Glucose-dependent insulinotropic receptor)

Beyond the preview

Go deeper on ps297.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ps297.

Explore the full profile